Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Version 2 2024-06-06, 05:21Version 2 2024-06-06, 05:21
Version 1 2023-06-07, 01:47Version 1 2023-06-07, 01:47
journal contribution
posted on 2024-06-06, 05:21authored byKM Field, J Simes, AK Nowak, L Cher, H Wheeler, EJ Hovey, CSB Brown, EH Barnes, K Sawkins, Ann LivingstoneAnn Livingstone, R Freilich, PM Phal, G Fitt, MA Rosenthal, I Arzhintar, L Garrett, A Byrne, A Dowling, N Ranieri, R Jennens, F Osmond, WK Patterson, A Phay, F Abell, L Plowman, J Flynn, E Hovey, H Kilsby, S Kirby-Lewis, N Singhal, S Smith, M Whelan, P Inglis, A Ives, A Nowak, S Lobb, S Begbie, P Williams, Z Lwin, N Woodward, G Crosbie, R Harrup, L Pyszkowski, S Gauden, A Neville
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma